Zymeworks IncCommon Stock is a biotechnology business based in the US. Zymeworks IncCommon Stock shares (ZYME) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.17 – a decrease of 5.42% over the previous week. Zymeworks IncCommon Stock employs 290 staff and has a trailing 12-month revenue of around $62.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $13.17 |
|---|---|
| 52-week range | $6.51 - $14.04 |
| 50-day moving average | $11.82 |
| 200-day moving average | $10.43 |
| Wall St. target price | $14.79 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.50 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.48 from 2024-10-18
| 1 week (2024-10-15) | -3.20% |
|---|---|
| 1 month (2024-09-20) | 2.98% |
| 3 months (2024-07-22) | 31.38% |
| 6 months (2024-04-22) | 54.76% |
| 1 year (2023-10-20) | 87.48% |
|---|---|
| 2 years (2022-10-21) | 115.68% |
| 3 years (2021-10-22) | 23 |
| 5 years (2019-10-22) | 30.51 |
| Revenue TTM | $62.7 million |
|---|---|
| Gross profit TTM | $203.8 million |
| Return on assets TTM | -13.62% |
| Return on equity TTM | -26.32% |
| Profit margin | -179.42% |
| Book value | $5.73 |
| Market Capitalization | $989.3 million |
TTM: trailing 12 months
We're not expecting Zymeworks IncCommon Stock to pay a dividend over the next 12 months.
Over the last 12 months, Zymeworks IncCommon Stock's shares have ranged in value from as little as $6.5124 up to $14.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zymeworks IncCommon Stock's is 1.193. This would suggest that Zymeworks IncCommon Stock's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd. ; Celgene Corporation; Celgene Alpine Investment Co.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi Invest is a commission-free platform with both active and automated investment accounts.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.